Thiamine®

Thiamine Hydrochloride 50 mg/ml solution for injection (thiamine hydrochloride): Please refer to the Summary of Product Characteristics (SPC) before prescribing. 

Abbreviated Prescribing Information.

Presentation: Solution for injection. Clear, colourless solution in a 5ml glass ampoule. Indications: Thiamine deficiency conditions where oral therapy is not possible. Treatment of Wernicke´s encephalopathy associated with alcohol addiction and/or alcohol withdrawal syndrome and prevention of Wernicke-Korsakoff syndrome. For the treatment of peripheral neuropathy (dry beriberi) and heart failure (wet beriberi) due to thiamine malabsorption. For the treatment of anorexia – refeeding syndrome. Dosage and administration: The condition of the patient and the extent of the disease need to be taken into consideration. A nutritional therapist should be consulted if uncertain. Thiamine is able to be administered via intramuscular (IM) and slow intravenous (IV) injection. Treatment of Wernicke´s encephalopathy associated with Alcohol addiction and/or alcohol withdrawal syndrome and prevention of Wernicke-Korsakoff syndrome: 500 mg by intravenous route 3 times/day for at least 2 days (up to 1000 mg/dose during the first 12 hours may be used). In case of favourable response the treatment can be continued with 250 mg by intramuscular or intravenous route 1 time/day for 5 days or until there is no further improvement. When administering intravenously thiamine should be diluted with 50ml to 100ml of physiological saline and administered over 30 minutes duration.  This product should be used immediately upon dilution. In the outpatient detoxification setting, the administration of a course of thiamine 250 mg intramuscularly for 5 days has been recommended over oral therapy. Clinical experience indicates that patients with WE may benefit from continued treatment for more than 2 weeks. In alcoholics without WE, oral thiamine administration is as effective as parenteral administration after 5 days. Beriberi: Treatment: 10 mg to 25 mg/day by intramuscular injection or slow intravenous infusion for 2 weeks. IV doses of 100 mg/day or even higher may be needed in severe cases, for example 500 mg three times a day could be used. Malabsorption due to gastrectomy: The standard recommendation for postoperative supplementation for thiamine in symptomatic patients is 50–100 mg/day IV or IM for 7-14 days and then 10 mg/day orally until complete recovery of neurologic symptoms. The standard recommendation for daily oral supplementation after surgery in asymptomatic patients is 50-100 mg/day. Patients with a history of bariatric surgery who present with any signs of gastrointestinal distress should receive thiamine preventively. Thiamine administration of 100 mg IV or IM daily, or enterally if tolerated, has been suggested for any patient with more than 3-4 week of emesis. Anorexia – refeeding syndrome: It is recommended that thiamine supplementation (100-300 mg/day) is given during the first 3 days in within the intensive care unit for all patients with suspected thiamine deficiency to prevent neurological adverse effects from too rapid glucose delivery. Contraindications: Hypersensitivity to thiamine hydrochloride or to any of the excipients. Warnings and Precautions: Intramuscular or intravenous injection of thiamine may cause hypersensitivity reactions including anaphylactic shock. Facilities for treating anaphylaxis (including resuscitation facilities) should be available when parenteral thiamine is administered. Interactions: The thiamine antagonist's thiosemicarbazone, ifosfamide, other fluoropyrimidines (e.g. capecitabine) and 5-fluorouracil can neutralise the effect of thiamine. Diuretics, e.g. furosemide may increase urinary thiamine excretion. Patients using any of these treatments may need their thiamine dose adjusted. Thiamine could give false positive results for urobilinogen determination by the Ehrlich's reaction. High doses of thiamine may interfere with spectrophotometric assays of theophylline plasma concentration. Fertility, pregnancy and lactation: Pregnancy: There are no or limited data from the use of high levels of thiamine (>50 mg/day) in pregnant women. However, there are no known risks, when thiamine is used during pregnancy at recommended daily intake levels. As a precautionary measure, it is preferable to avoid the use of thiamine during pregnancy. Breastfeeding: Thiamine is excreted in human milk. At recommended daily intake levels, no effects on the breastfed newborns/infants are anticipated. However, there is insufficient information on the levels and possible effects of excretion of thiamine in human milk after administration of high levels of thiamine (>50 mg/day). A risk to the suckling child cannot be excluded. Fertility: There are no data on possible effects on fertility after administration of high doses of thiamine (>50 mg/day). Undesirable effects: Frequency not known: Local irritation at the injection site, anaphylaxis, exanthem, pruritus, urticaria, acute blood pressure decrease, dyspnoea. Overdose: Refer to SPC. Legal Category: POM. NHS Price: £16.23 (one box of 6 x 5 mL ampoules). Marketing Authorisation Holder: Pemberton Laboratories (UK) Limited, 5 The Heights, Weybridge, KT13 0NY, United Kingdom. MA Number: PL 55469/0002. Full prescribing information available from: Galen Limited, Seagoe Industrial Estate, Craigavon, BT63 5UA, United Kingdom. Date of Preparation: October 2024.